Article metrics

Download PDFPDF

719 Phase 1 clinical trial design of ZM008, a first-in-class anti LLT1 antibody is a promising therapy for multiple solid cancers

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023182015
Dec 20235204
Jan 20245107
Feb 20245805
Mar 20243802
Apr 20243802
May 20244605
Jun 20246404
Jul 20246401
Aug 20241600
Sep 20246605
Oct 20245208
Nov 20248004
Dec 20244005
Jan 202538014
Feb 2025802
Mar 2025205
Apr 2025101
May 2025003
Jun 2025002
Total896094